Research Paper Volume 16, Issue 2 pp 1218—1236
Development and validation of a combined cuproptosis and immunogenic cell death prognostic model for diffuse large B-cell lymphoma
Figure 7. Drug sensitivity analysis. (A) Crizotinib, (B) Dasatinib, (C) GW843682X, (D) MG-132, (E) Paclitaxel, (F) Rapamycin, (G) Saracatinib, (H) VX-680, (I) Sunitinib and (J) TAE684. (K–T) Correlation analysis of the risk score and drug sensitivity (IC50).